Ontological type

TYPE: Physiological process/Pathophysiological state. Explanation: Univentricular function is best described as a physiological process within integrative physiology[1][3] that represents a pathophysiological state where one ventricle is incapable of independently supporting either the pulmonary or systemic circulation[1][3]. It relates to its parent domain (integrative physiology) as a specific manifestation of integrated cardiovascular function under conditions of congenital heart defects, encompassing the complex hemodynamics, compensatory mechanisms, and clinical management strategies characteristic of systems-level cardiology[2][3]. Rather than being a theory, institution, or isolated practice, it is a recognized physiological phenomenon that integrates anatomy, hemodynamics, and surgical intervention into a unified clinical framework[1][3].

Surgical Palliation Strategies

The main staged surgical palliation strategies for univentricular hearts are: Stage 1 (Norwood procedure) in neonates, providing unobstructed systemic outflow, controlled pulmonary blood flow via shunts (e.g., modified Blalock-Taussig), and mixing of systemic/pulmonary venous blood, altering physiology by making the single ventricle pump to both circulations in parallel with high volume load[2][3][4][5]. Stage 2 (Glenn or Hemi-Fontan) at 4-6 months connects the superior vena cava directly to the pulmonary artery, reducing ventricular preload by directing upper body venous return passively to lungs and closing prior shunts, thus lowering volume load on the ventricle[1][2][3][5]. Stage 3 (Fontan procedure) at 1.5-4 years connects the inferior vena cava to the pulmonary artery, creating total cavopulmonary connection where all systemic venous return flows passively to lungs without ventricular support, increasing afterload sensitivity but separating pulmonary from systemic circulations[1][2][3][5].

Hemodynamic Principles

In univentricular circulation, key hemodynamic principles include complete mixing of systemic and pulmonary venous blood at the ventricular level, with systemic-pulmonary flow balance governed by the ratio of pulmonary to systemic vascular resistances (PVR/SVR), often requiring controlled pulmonary stenosis to prevent overcirculation[1][3]. Pressure-volume relationships are altered as the single ventricle handles both circulations, increasing the risk of contractile dysfunction compared to biventricular physiology where separate ventricles manage distinct low- and high-pressure systems[4]. Ventricular-arterial coupling differs markedly, lacking parallel circuits and relying on shunts like patent ductus arteriosus for systemic output in outflow obstruction cases, unlike the efficient series-parallel setup in normal hearts[1][2].

Long-Term Outcomes

Patients with univentricular circulation post-Fontan palliation have 60-80% survival at 20 years, with risks increasing over time due to elevated central venous pressure (CVP) causing organ dysfunction including renal impairment (e.g., microalbuminuria), liver dysfunction, heart failure, arrhythmias, and thromboembolism; exercise capacity and quality of life (QOL) decline long-term, though some maintain good functional status.[1][3][4] Without Fontan, survival is poorer (e.g., 73% at 40 years, 53% at 50 years), with high mortality from heart failure and arrhythmias.[5] Prognosis predictors include right ventricular (RV) dominance (worse survival vs. left: 71% vs. 91% at 10 years), QRS prolongation, renal impairment, and birth era (improved survival recently).[1][2][5]

1968–1989

Foundational Surgical Physiology

Establishing the Fontan surgical strategy as a physiologic solution for single-ventricle defects was the central concern. Surgical innovation and hemodynamic conceptualization reframed single-ventricle circulation as a venous-return–limited systemic circuit. Experimental physiology, operative technique development, and early clinical series created the operative criteria and intraoperative practices that codified the Fontan principle. Institutional adoption and outcome reporting provided the empirical basis for subsequent clinical and research agendas.

No major cross-period event is available for this era.

1990–2009

Recognition of Long-term Sequelae

Characterization of chronic multiorgan consequences of the Fontan circulation became the dominant focus. Longitudinal cohorts, registries, and pathology studies linked sustained systemic venous hypertension to hepatic remodeling, progressive diastolic dysfunction, and impaired exercise capacity. Hemodynamic investigations and outcome surveillance reframed success metrics toward long-term organ preservation and functional status. Consensus reports and multicenter data consolidated attention on late morbidity as a primary clinical problem.

No major cross-period event is available for this era.

2010–2025

Imaging-Biomarker–Guided Care

Integration of advanced imaging, circulating biomarkers, and device strategies to personalize surveillance and therapy defines this era. Cardiac magnetic resonance, echocardiographic techniques, and validated biomarkers have become central tools for objective assessment of univentricular function and Fontan circuit performance. Multidisciplinary programs, guideline harmonization, and selective mechanical support interventions operationalize risk stratification and targeted management. These methods concentrate clinical decision-making on measurable physiologic parameters to guide timing of interventions and longitudinal care.

The Fontan circulation is a venous‑return–limited systemic circuit whose diastolic dysfunction, constrained systemic venous return, reduced exercise capacity, and hepatic remodeling across variants and conversions drive long‑term outcomes and surveillance priorities[1][2][3][4][5][6][7]. Imaging‑driven characterization of single‑ventricle right‑heart function—centered on MRI and echocardiography and harmonized by adult congenital imaging guidelines—combined with biomarker candidates such as GDF‑15 and advancing pediatric VAD experience, underpins diagnosis, prognosis, and management algorithms for the Fontan population[8][9][10][11][12][13][14][15].

Some influential works that stand out in this era include the following. During the Imaging-Biomarker–Guided Care era (2010–2025), the ASE guidelines[10] established standardized echocardiographic methods for right ventricular assessment that were directly applied to evaluate univentricular function in Fontan patients, providing reproducible imaging biomarkers for clinical care and multicenter research. These harmonized metrics improved early detection of dysfunction, enabled longitudinal monitoring and risk stratification, and underpinned biomarker-driven trials and guideline-based management.

Foundational Surgical Physiology era

Scott D. Solomon and Wyman W. Lai

Scott D. Solomon[1] has been associated with Harvard University[3] and the University of California, San Francisco[4] during the Imaging-Biomarker–Guided Care era. His key contribution in this era comes from the Guidelines for the Echocardiographic Assessment of the Right Heart in Adults: A Report from the American Society of Echocardiography[5], which standardized right-heart imaging and diagnostics to support objective decision-making for univentricular function and Fontan circuit surveillance. Wyman W. Lai[2] has also been associated with Harvard University[3] and the University of California, San Francisco[4] in this era. Lai's key contribution centers on the Guidelines for the Echocardiographic Assessment of the Right Heart in Adults: A Report from the American Society of Echocardiography[5], promoting consistent right-heart evaluation and informing imaging-driven surveillance strategies for univentricular function in Fontan physiology.